{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:36:35Z","timestamp":1783474595781,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ijcard.2024.132029","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T22:27:48Z","timestamp":1712356068000},"page":"132029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors"],"prefix":"10.1016","volume":"407","author":[{"given":"Manyun","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhu","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Shi Kai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijcard.2024.132029_bb0005","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.ijcard.2024.132029_bb0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132029_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ijcard.2024.132029_bb0020","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ (Clinical research ed)."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132029_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2022.03.006","article-title":"Liver immune-related adverse effects of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity score matched study with competing risk analyses","volume":"34","author":"Zhou","year":"2022","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132029_bb0030","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00432-022-04425-z","article-title":"Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1\/PD-L1 inhibitor monotherapy","volume":"149","author":"Yamaguchi","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132029_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101380","article-title":"Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study","volume":"48","author":"Chan","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"issue":"16","key":"10.1016\/j.ijcard.2024.132029_bb0040","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2024.132029_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132029_bb0050","first-page":"5","article-title":"Adverse cardiovascular complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched cohort study with competing risk analysis","volume":"8","author":"Zhou","year":"2022","journal-title":"Cardiooncology"},{"issue":"7","key":"10.1016\/j.ijcard.2024.132029_bb0055","article-title":"ICIs-related cardiotoxicity in different types of cancer","volume":"9","author":"Dong","year":"2022","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"18","key":"10.1016\/j.ijcard.2024.132029_bb0060","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132029_bb0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"10.1016\/j.ijcard.2024.132029_bb0070","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132029_bb0075","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","article-title":"Pericardial effusion under nivolumab: case-reports and review of the literature","volume":"7","author":"Saade","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.ijcard.2024.132029_bb0080","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/1759-7714.13399","article-title":"Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"11","author":"Harada","year":"2020","journal-title":"Thorac. Cancer."},{"issue":"22","key":"10.1016\/j.ijcard.2024.132029_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab158","article-title":"Neutrophil\u2013lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis","volume":"42","author":"Zhang","year":"2021","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.ijcard.2024.132029_bb0090","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil\u2013lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.ijcard.2024.132029_bb0095","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1093\/eurheartj\/ehab166","article-title":"The neutrophil\u2013lymphocyte ratio: considerations for clinical application","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132029_bb0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2020.08.033","article-title":"Cardiotoxic mechanisms of cancer immunotherapy - a systematic review","volume":"323","author":"Lobenwein","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132029_bb0105","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132029_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-020-00925-8","article-title":"New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity","volume":"22","author":"Khunger","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"21","key":"10.1016\/j.ijcard.2024.132029_bb0115","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","article-title":"Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology","volume":"136","author":"Varricchi","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcard.2024.132029_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132029_bb0125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/abbs\/gmab020","article-title":"The binding epitope of sintilimab on PD-1 revealed by AbMap","volume":"53","author":"Ma","year":"2021","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"issue":"3","key":"10.1016\/j.ijcard.2024.132029_bb0130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2024.132029_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A Promising Anti-Tumor PD-1 Antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132029_bb0140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ijcard.2024.132029_bb0145","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3389\/fimmu.2020.02076","article-title":"Sintilimab-induced autoimmune diabetes in a patient with the anti-tumor effect of partial regression","volume":"11","author":"Wen","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132029_bb0150","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.21037\/apm-20-1310","article-title":"An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report","volume":"9","author":"Gao","year":"2020","journal-title":"Ann Palliat Med."},{"issue":"6","key":"10.1016\/j.ijcard.2024.132029_bb0155","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/jcpt.13217","article-title":"Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab","volume":"45","author":"Hu","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ijcard.2024.132029_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.12.030","article-title":"Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy","volume":"128","author":"Ni","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ijcard.2024.132029_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CJI.0000000000000314","article-title":"Paraneoplastic encephalitis and enteric neuropathy associated with anti-Hu antibody in a patient following immune-checkpoint inhibitor therapy","volume":"43","author":"Kang","year":"2020","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132029_bb0170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132029_bb0175","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/ajco.13326","article-title":"Cardiovascular immune-related adverse events: evaluation, diagnosis and management","volume":"16","author":"Liu","year":"2020","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132029_bb0180","first-page":"39","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated cardiovascular toxicities","volume":"38","author":"Wu","year":"2022","journal-title":"Acta Cardiol. Sin."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132029_bb0185","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/imt-2021-0223","article-title":"PD-1\/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review","volume":"14","author":"Li","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijcard.2024.132029_bb0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-pharmtox-010919-023451","article-title":"Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure","volume":"61","author":"Waliany","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"10","key":"10.1016\/j.ijcard.2024.132029_bb0195","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology","volume":"119","author":"Chen","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"issue":"6","key":"10.1016\/j.ijcard.2024.132029_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324006235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324006235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T10:22:02Z","timestamp":1715768522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324006235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"alternative-id":["S0167527324006235"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132029","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132029"}}